Last reviewed 2026-06-02 · How we verify

Part A:AZD8233

AstraZeneca · Phase 1 active Small molecule ✓ Verified Jun 2026

Part A:AZD8233 is a Small molecule drug developed by AstraZeneca. It is currently in Phase 1 development.

AZD8233 is being studied in a clinical trial for the condition of dyslipidemia. The trial, NCT04823611, is evaluating the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of AZD8233 in participants with dyslipidemia.

Likelihood of approval

12.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Big-pharma sponsor +3.0pp
AstraZeneca is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Part A:AZD8233
Sponsor	AstraZeneca
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of AZD8233 in Participants With Dyslipidemia. (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Part A:AZD8233 CI brief — competitive landscape report
Part A:AZD8233 updates RSS · CI watch RSS
AstraZeneca portfolio CI

Frequently asked questions about Part A:AZD8233

What is Part A:AZD8233?

Part A:AZD8233 is a Small molecule drug developed by AstraZeneca.

Who makes Part A:AZD8233?

Part A:AZD8233 is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).

What development phase is Part A:AZD8233 in?

Part A:AZD8233 is in Phase 1.

Manufacturer: AstraZeneca — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing